TRDAEntrada Therapeutics, Inc.

Nasdaq entradatx.com


$ 14.50 $ 0.16 (1.12 %)    

Monday, 13-May-2024 13:38:53 EDT
QQQ $ 442.56 $ -0.85 (-0.19 %)
DIA $ 394.41 $ -1.90 (-0.48 %)
SPY $ 520.54 $ -2.05 (-0.39 %)
TLT $ 90.56 $ 0.23 (0.25 %)
GLD $ 216.25 $ -0.91 (-0.42 %)
$ 14.34
$ 14.63
$ 0.00 x 0
$ 0.00 x 0
$ 14.41 - $ 14.79
$ 10.62 - $ 18.44
40,887
na
498.9M
$ 0.79
$ 19.38
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 05-07-2024 03-31-2024 10-Q
2 03-13-2024 12-31-2023 10-K
3 11-07-2023 09-30-2023 10-Q
4 08-08-2023 06-30-2023 10-Q
5 05-10-2023 03-31-2023 10-Q
6 03-06-2023 12-31-2022 10-K
7 11-07-2022 09-30-2022 10-Q
8 08-11-2022 06-30-2022 10-Q
9 05-12-2022 03-31-2022 10-Q
10 03-15-2022 12-31-2021 10-K
11 12-09-2021 09-30-2021 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

 insiders-buying-americas-car-mart-and-2-other-stocks

Although U.S. stocks closed lower on Wednesday, there were a few notable insider trades.

 around-5m-bet-on-this-communication-services-stock-check-out-these-4-stocks-insiders-are-buying

Although U.S. stocks closed higher on Thursday, there were a few notable insider trades.

 hc-wainwright--co-reiterates-buy-on-entrada-therapeutics-maintains-20-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $2...

 entrada-therapeutics-q4-gaap-eps-029-misses-017-estimate-sales-4185m-beat-2369m-estimate

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate o...

 oppenheimer-initiates-coverage-on-entrada-therapeutics-with-outperform-rating-announces-price-target-of-22

Oppenheimer analyst Hartaj Singh initiates coverage on Entrada Therapeutics (NASDAQ:TRDA) with a Outperform rating and annou...

 hc-wainwright--co-maintains-buy-on-entrada-therapeutics-lowers-price-target-to-20

HC Wainwright & Co. analyst Raghuram Selvaraju maintains Entrada Therapeutics (NASDAQ:TRDA) with a Buy and lowers the pr...

 why-is-neuromuscular-disease-focused-entrada-therapeutics-shares-trading-lower-today

Entrada Therapeutics Inc (NASDAQ: TRDA) shares are trading lower after the company announced updates on ENTR-601-44 in 

 entrada-therapeutics-q3-eps-102-may-not-be-comparable-to-074-estimate-sales-4373m-may-not-be-comparable-to-960m-estimate

Entrada Therapeutics (NASDAQ:TRDA) reported quarterly earnings of $1.02 per share which beat the analyst consensus estimate of ...

 hc-wainwright--co-reiterates-buy-on-entrada-therapeutics-maintains-25-price-target

HC Wainwright & Co. analyst Raghuram Selvaraju reiterates Entrada Therapeutics (NASDAQ:TRDA) with a Buy and maintains $2...

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION